Policy & Regulation
InnoCare granted FDA clearance for TYK2 inhibitor trial in atopic dermatitis
11 June 2024 -

Commercial-stage biopharmaceutical company InnoCare Pharma (HKEX:09969) (SSE:688428) announced on Tuesday that it has received US Food and Drug Administration (FDA) clearance for a clinical trial of its TYK2 (Tyrosine Kinase 2) inhibitor, ICP-332, for treating moderate-to-severe atopic dermatitis (AD).

ICP-332 demonstrated positive results in a prior China Phase II study, showing better efficacy than other AD treatments. The drug targets the JAK-STAT signalling pathway, crucial in AD development.

At present, no TYK2 inhibitors have obtained marketing approval for the treatment of AD anywhere in the world.